All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.

Details

Serval ID
serval:BIB_97CF39EFF89C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.
Journal
Current opinion in biotechnology
Author(s)
Lanitis E., Coukos G., Irving M.
ISSN
1879-0429 (Electronic)
ISSN-L
0958-1669
Publication state
Published
Issued date
10/2020
Peer-reviewed
Oui
Volume
65
Pages
75-87
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Synthetic biology has been transformative to the treatment of advanced hematological malignancies by chimeric antigen receptor (CAR)-engineered T cells. A range of obstacles are now understood to limit the responses of solid epithelial-derived tumors to CAR therapy. For example, inefficient tumor homing and a fortified stroma can restrain the number of CAR-T cells reaching the tumor bed. Upon transendothelial migration across the tumor vasculature, CAR-T cells face a highly suppressive microenvironment that can quickly render them hypofunctional. Safety also remains a critical issue for advancing CAR therapy of solid tumors. Innovative CAR design as well as coengineering and combinatorial treatment strategies with oncolytic adenovirus, radiotherapy, vaccines, chemotherapy, small molecules and monoclonal antibodies hold tremendous potential to support CAR-T cell control of solid tumors, either by directly promoting CAR-T cell function, or/and by re-programming the TME and harnessing the endogenous immune system against the tumor.
Pubmed
Web of science
Open Access
Yes
Create date
03/03/2020 16:01
Last modification date
13/01/2021 7:23
Usage data